A1 Refereed original research article in a scientific journal

Analysis of left ventricular mass in untreated men and in men treated with agalsidase-beta: data from the Fabry Registry



Authors: Germain DP, Weidemann F, Abiose A, Patel MR, Cizmarik M, Cole JA, Beitner-Johnson D, Benistan K, Cabrera G, Charrow J, Kantola I, Linhart A, Nicholls K, Niemann M, Scott CR, Sims K, Waldek S, Warnock DG, Strotmann J

Publisher: NATURE PUBLISHING GROUP

Publication year: 2013

Journal: Genetics in Medicine

Journal name in source: GENETICS IN MEDICINE

Journal acronym: GENET MED

Number in series: 12

Volume: 15

Issue: 12

First page : 958

Last page: 965

Number of pages: 8

ISSN: 1098-3600

DOI: https://doi.org/10.1038/gim.2013.53


Abstract
Conclusion: Agalsidase-beta treatment for >= 2 years may improve or stabilize left-ventricular mass in men with Fabry disease. Further investigations may determine whether early intervention and stabilization of LVM are correlated with clinical outcomes.



Last updated on 2024-26-11 at 22:55